



Vol 7 No 5 Research article
Prevalence of opioid adverse events in chronic non-malignant 
pain: systematic review of randomised trials of oral opioids
R Andrew Moore and Henry J McQuay
Pain Research and Nuffield Department of Anaesthetics, University of Oxford, Oxford Radcliffe Hospital, Oxford, UK
Corresponding author: R Andrew Moore, andrew.moore@pru.ox.ac.uk
Received: 18 Apr 2005 Revisions requested: 18 May 2005 Revisions received: 24 May 2005 Accepted: 6 Jun 2005 Published: 28 Jun 2005
Arthritis Research & Therapy 2005, 7:R1046-R1051 (DOI 10.1186/ar1782)
This article is online at: http://arthritis-research.com/content/7/5/R1046
© 2005 Moore and McQuay; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Adverse events of opioids may restrict their use in non-cancer
pain. Analysis of the incidence of common adverse events in
trials conducted in non-cancer pain has usually been limited to
opioids used to treat severe pain according to the WHO three-
step ladder. To examine the incidence of common adverse
events of opioids in non-cancer pain, a systematic review and
meta-analysis of information from randomised trials of all opioids
in non-cancer pain was undertaken. Studies used were
published randomised trials of oral opioid in non-cancer pain,
with placebo or active comparator. Thirty-four trials with 5,546
patients were included with 4,212 patients contributing some
information on opioid adverse events. Most opioids used
(accounting for 90% of patients) were for treating moderate
rather than severe pain. Including trials without a placebo
increased the amount of information available by 1.4 times.
Because of clinical heterogeneity in condition, opioid, opioid
dose, duration, and use of titration, only broad results could be
calculated. Use of any oral opioid produced higher rates of
adverse events than did placebo. Dry mouth (affecting 25% of
patients), nausea (21%), and constipation (15%) were the most
common adverse events. A substantial proportion of patients on
opioids (22%) withdrew because of adverse events. Because
most trials were short, less than four weeks, and because few
titrated the dose, these results have limited applicability to
longer-term use of opioids in clinical practice. Suggestions for
improved studies are made.
Introduction
Opioids are advocated by WHO for cancer pain [1], but their
role in chronic non-cancer pain is more controversial. It has
been argued that certain types of chronic pain, like neuro-
pathic pain, do not respond to opioids [2], although some
patients with neuropathic pain have been shown to respond
well to opioids, as do patients with chronic nociceptive pain
[3]. Concerns have been expressed about the safety of long-
term opioid administration [4] because of adverse effects [5],
development of tolerance to the analgesic effect [6], addic-
tion, and drug diversion [7]. Guidelines for responsible use of
opioids in chronic non-cancer pain [8-10] reflect concern over
these problems.
At least one recent systematic review has investigated efficacy
and safety of oral opioids in placebo-controlled randomised tri-
als in chronic non-malignant pain [11]. It included 11 trials in
which patients received different oral opioids, doses, and dos-
ing regimens, over varying periods of time, and in patients with
arthritis, musculoskeletal pain, neuropathic pain, and mixed
conditions. Adverse event rates could be calculated for sev-
eral adverse events, and numbers needed to harm were calcu-
lated, which were as low as 3 for constipation, and 5 for
nausea and somnolence. Constipation (affecting 41%), nau-
sea (32%) and somnolence (29%) were the most common
adverse events.
The fact that only placebo-controlled trials were included
meant that any trials of different opioids, or different dosing
regimens, or different formulations that did not have a placebo
group were not analysed. The study was additionally limited to
opioids (fentanyl, hydromorphone, methadone, morphine, oxy-
codone, oxymorphone) used to treat severe pain according to
the WHO three-step ladder, and did not include other opioids,
like codeine, dextropoxyphene, or tramadol, often used to treat
moderate pain. The limited number of trials also meant that
sensitivity analysis for different conditions (arthritis, muscu-
loskeletal, or neuropathic pain) was not feasible.Arthritis Research & Therapy    Vol 7 No 5    Moore and McQuay 
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To address these points, a further systematic review was con-
ducted to include all randomised double blind trials of any opi-
oid, alone or in combination with other analgesics, irrespective
of their being placebo or active controlled. There were several
aims. First, to establish how much information was lost if anal-
yses were limited to placebo-controlled trials only. Second,
because there was no common comparator for statistical anal-
ysis, to establish prevalence rates for oral opioid use in chronic
non-malignant pain. Third, to investigate any major differences
in opioid adverse events in chronic non-malignant pain of dif-
ferent aetiology.
Methods
Broad free-text searches were conducted of Medline (1966 to
August 2004), EMBASE (1980 to August 2004), Cochrane
Library (on-line August 2004) and the Oxford Pain Relief Data-
base (1950 to 1994 [12]), without restriction of language.
Reference lists of reports and reviews were also searched.
Abstracts, review articles and unpublished reports were not
considered. Authors were not contacted for original data.
Inclusion criteria were randomised double blind comparisons
of oral opioid with placebo or an active comparator in chronic
non-cancer pain. Only double blind studies with at least 10
adult patients completing each treatment arm reporting on
adverse events were included. Inclusion was based on a con-
sensus of all reviewers.
QUOROM guidelines for reporting meta-analyses were fol-
lowed [13]. Each report was scored for quality and validity
using a three-item (1 to 5) quality scale [14] assessing the
quality of randomisation, double-blinding and reporting on
withdrawals and dropouts. The minimum score for inclusion
was 2 points (one each for randomisation and blinding).
Information about treatments and controls, numbers ran-
domised and analysed, type and dose of opioid, and duration
of study was extracted. Information about adverse events was
looked for and extracted, particularly the number of patients
experiencing any adverse event, withdrawing because of
adverse events or lack of efficacy, and patients experiencing
particular adverse events.
There was prior intent to analyse data for all patients, irrespec-
tive of condition, and to analyse separately for patients with
arthritis (any site), other musculoskeletal conditions (back
pain, for instance), neuropathic pain, and pain of mixed origin.
No statistical analysis was planned, as it was considered
unlikely that there would be sufficient consistency of drug
used, dose, titration regimen, duration, or comparator that
would provide sufficient information for any sensible compara-
tor. It was planned to estimate the prevalence of adverse
events for patients receiving oral opioids or placebo, both
overall and for each condition. Adverse event rates would be
calculated with a 95% confidence interval.
Results
Searches found 35 trials with a total of 5,546 patients,
although one trial [15] had no interpretable data and contrib-
uted no patients to the analysis. Most trials and patients were
in arthritis or musculoskeletal conditions, with few patients
with neuropathic pain, and some in mixed nociceptive and neu-
ropathic conditions (Table 1). All but one trial had quality
scores of 3 or more out of 5. Twenty-eight trials were of one to
four weeks. Four were shorter (three to six days) and two were
longer (one of 30 days, and one of 8 weeks). Adverse events
were not usually recorded using formal diaries (three trials) or
questionnaires (two trials). Most trials either collected volun-
teered information, or asked general questions about adverse
events. Detailed information on each trial, together with the ref-
erences of the trials included, is in Additional file 1.
The number of patients given different opioids in each condi-
tion, and overall, is shown in Table 2. Overall, 4,212 patients
contributed some data on opioid adverse events. Just over half
the patients received tramadol or tramadol plus paracetamol,
and combinations of codeine or dextropropoxyphene with
paracetamol contributed another quarter. Other than tramadol,
morphine was the only opioid to have been tested in each con-
dition. Only 10% of patients received oral opioids (morphine
or oxycodone) to treat severe pain. Some form of initial dose
titration was mentioned in 14 of the 34 trials. Dose titration
was uncommon in arthritis or musculoskeletal conditions (3/
16 trials in arthritis, 4/10 trials in musculoskeletal pain), but
very common in trials involving neuropathic pain (4/5) or pain
of mixed origin (3/3).
Of the 34 trials contributing data to the analysis, 16 (47%) had
a placebo control. Of the 5,546 patients, 2293 (41%) were in
trials that had a placebo control. The frequency of placebo
control was highest in neuropathic pain studies, with four of
five trials and 87% of patients. The policy of including trials
without a placebo increased the potential amount of informa-
tion by about 1.4 times. Other comparators used included
paracetamol, diclofenac, and nortriptyline, each in a single trial.
The overall rates of patients experiencing any adverse event,
adverse event or lack of efficacy withdrawal, or particular
adverse events for both opioid and placebo are shown in Table
3 and Fig. 1. Event rates were higher for opioids than placebo
for all adverse events, with the exception of lack of efficacy
withdrawal, when placebo was higher than opioid.
In these relatively short-term trials, about half the patients
would experience at least one adverse event, and about one in
five would stop taking opioids because of the adverse event.
With opioids, the adverse events reported were those likely to
be encountered with the use of opioids, namely nausea or
vomiting, constipation, drowsiness and dizziness, all of which
were commonly reported in large samples of between 3,000
and 4,300 patients. Dry mouth and pruritus were reported inAvailable online http://arthritis-research.com/content/7/5/R1046
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relatively small numbers of patients in relatively small samples.
Event rates for particular adverse events were between 10%
and 25% (Table 3). Information was available from much fewer
patients receiving placebo. Typically, only a few tens of
patients out of several hundred enrolled in the trials reported
particular adverse events. For individual adverse events only
about 2% to 5% of patients were affected (Table 3).
These average results conceal very great variation between
individual trials. For instance, constipation in individual trials
could be reported in as few as 0%, and as high as 71%, and
nausea between 5% and 98% (Additional file 2). These large
variations typically were found in the smaller trials, and there
was no obvious relationship between high or low rates and
drug, dose, or dosing regimen.
Table 1
Randomised double blind trials of opioids in chronic non-malignant pain of different aetiology
Number of Number of
Condition Trials Patients Drug treaments Trial arms Contributing patients
Arthritis 16 2990 Opioid 24 2173
Placebo 7 445
Other comparator 2 447
Musculoskeletal 10 1648 Opioid 18 1561
Placebo 4 302
Other comparator 0 0
Neuropathic 5 302 Opioid 5 219
Placebo 4 178
Other comparator 1 46
Mixed conditions 3 606 Opioid 6 606
Placebo 1 49
Other comparator 0 0
Table 2
Opioids used in trials of non-malignant pain of different aetiology
Conditiona
Drug Arthritis Musculoskeletal Neuropathic Mixed All conditions
Codeine 51 46 97
Codeine + paracetamol 173 233 156 562
Dihydrocodeine 119 119
Dextropropoxyphene 129 56 185
Dextropropoxyphene + paracetamol 496 496
Morphine 222 61 59 49 391
Meptazinol 31 31
Oxycodone 47 50 97
Pentazocine 76 76
Tramadol 363 778 110 401 1652
Tramadol + paracetamol 197 309 506
Total 1826 1561 219 606 4212
aValues are numbers of patients treated with the different opioids.Arthritis Research & Therapy    Vol 7 No 5    Moore and McQuay 
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Different painful conditions produced generally similar pat-
terns of results, and Additional file 2 reports the details of the
number of trial arms, patients, average prevalence and range
of results found in individual trials. Fig. 2 shows the compari-
son pictorially. Event rates for each adverse event were
consistent for all four conditions, although there was a ten-
dency to lower adverse event rates in trials in mixed condi-
tions, and to some extent in neuropathic pain, where more
trials used dose titration rather than fixed dosing schedules.
Discussion
This systematic review is different from two previous reviews
of opioids in chronic non-malignant pain [11,16] in that it
accepted trials of any opioid rather than only trials of opioids
used to threat severe pain on the WHO ladder (morphine, oxy-
codone, fentanyl). More than 90% of the 4,212 patients
received oral opioids not usually used to treat severe pain on
the WHO three-step ladder. Because this review includes tri-
als that did not have a placebo comparator, information on
Table 3
Adverse events with oral opioid and placebo in randomised trials in chronic non-malignant pain
Oral opioid Placebo
Number of patients Event rate (%) Number of patients Event rate (%)
Adverse event With AE Total Average 95% CI With AE Total Average 95% CI
Patients experiencing any 
adverse event
1387 2743 51 49–53 122 404 30 26–34
Withdrawals
Adverse event withdrawal 933 4221 22 21–23 51 721 7.1 5.2–8.9
Lack of efficacy withdrawal 177 2719 6.5 5.6–7.4 135 679 20 17–23
Specific adverse events
Dry mouth 100 399 25 21–29 3 94 3.2 0–6.7
Nausea 902 4314 21 20–22 40 718 5.6 3.9–7.2
Constipation 606 4043 15 14–16 32 643 5.0 3.3–6.7
Dizziness 530 3899 14 13–15 28 623 4.5 2.9–6.1
Drowsiness or somnolence 425 3078 14 13–15 21 531 4.0 2.3–5.6
Pruritus 106 794 13 11–16 7 336 2.1 0.6–3.6
Vomiting 345 3330 10 9.3–11 12 497 2.4 1.1–3.8
AE, adverse event; CI, 95% confidence interval.
Figure 1
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adverse events was available from many more patients. In total,
information from 34 randomised trials with 5,546 patients was
available (Table 1), much more information than available in
previous reviews with 11 randomised trials and 1025 patients
[11] or 16 randomised trials with 1,427 patients [16]. The pol-
icy of including studies without a placebo comparator meant
that 1.4 times more information was available.
The trials included were of good reporting quality, with all but
one of the 34 contributing data having quality scores of 3 or
more out of the maximum of 5. For efficacy analysis, this level
of reporting quality is not likely to suffer bias associated with
lack of randomisation or blinding. Trials were of relatively short
duration, however, limiting their utility. Only two lasted longer
than four weeks, and only one was as long as eight weeks. It
is possible that this might limit how general the results might
be, as some tolerance to adverse events with opioids with
longer use is expected.
It could be argued that for most people with chronic non-
malignant pain for whom opioids are an option, oral opioids
other than morphine or oxycodone would be preferable. Here,
three-quarters of the information on opioids was in patients
receiving codeine or tramadol, alone or in combination with
paracetamol.
The great variety of opioid drugs used, with different doses,
different dosing schedules, different comparators, and in dif-
ferent conditions meant that no statistical analysis was possi-
ble. Many of the trials were small, so that the potential for large
effects from the random play of chance could not be excluded
[17]. Methods used to collect adverse event information also
varied, with few studies using diaries or questionnaires to
obtain information in a systematic way. Even in acute pain
studies, the method of adverse event ascertainment can influ-
ence measured adverse event prevalence [18]. Less than ade-
quate reporting of adverse event information in clinical trials is
relatively common [19]. Randomised trials may not detect all
adverse events, especially in small short-term studies. In these
circumstances, trying to draw any conclusions by comparing
one trial with another would not be prudent.
Because the literature on opioid use in chronic non-malignant
pain was known to be clinically heterogeneous, the prior intent
was only to provide overall prevalence for adverse events with
oral opioids in a general way. Several thousand patients con-
tributed information for many adverse events with opioids, with
the exception of pruritus and dry mouth, which were less fre-
quently reported (Table 3). About one patient in two experi-
enced at least one adverse event, and one in five discontinued
because of adverse events. Nausea (21%), constipation
(15%), dizziness (14%), and drowsiness or somnolence
(14%) were the most common particular adverse events. This
was similar in order but lower in frequency than that found
previously with other opioids in chronic non-malignant pain
(constipation, 41%; nausea, 32%; and somnolence, 29%) [9].
Adverse event rates were similar in four separate clinical con-
ditions of arthritis pain, musculoskeletal pain, neuropathic
pain, and pain of mixed nociceptive and neuropathic origin.
Somewhat lower adverse event rates in the latter categories
might have been associated with a higher use of dose titration.
Adverse events with opioids were clearly higher than with pla-
cebo (Fig. 1, Table 3), as expected. Rates of adverse events
with placebo were not unlike those found in young healthy indi-
viduals in the USA and Germany, three decades apart [20,21],
where fatigue (37% to 65%), pain in muscles and joints (5%
to 13%), dry mouth (3% to 5%), constipation (3% to 4%), nau-
sea (1% to 3%) and vomiting (0% to 2%) were not infrequent.
Many other symptoms were mentioned in high frequency. A
large systematic review of constipation prevalence studies in
North America [22] found rates between about 2% and 27%,
but mostly about 15%, considerably higher than the 5% found
for placebo in the clinical trials, and the same as for patients
receiving opioids for chronic non-malignant pain (Table 3).
Future trials should consider a number of crucial variables,
including dose. The higher frequency of adverse events with
opioids used to treat severe pain [11] than with opioids more
often used to treat moderate pain found in this review, but with
similar rank order, may be explained by higher dose equiva-
lents with the former. Duration is also important. Patients start-
ing on opioids are usually told to expect initial adverse events,
such as nausea and drowsiness, but that these will improve
rapidly. Judging the adverse event profile of long-term opioid
use from short-term trials is unlikely to be satisfactory for
extrapolation to longer-term use in clinical practice.
Similarly, the naivety of the patients to opioids may be an issue
in adverse event incidence, and we were unable to analyse this
data set by previous opioid exposure. In real clinical life as
opposed to trials, dose is usually titrated. That was the case in
some of these trials, particularly in neuropathic pain, but not
many. We were unable to test whether adverse effects inci-
dence was different between trials with dose titration and trials
using a fixed dose. All of these points are relevant for the
design and conduct of future trials.
Conclusion
The review demonstrates that randomised trials of opioids in
chronic non-malignant pain have been predominantly of a
short duration, arguably too short to satisfy modern require-
ments of trial design in chronic pain. Adverse event information
must therefore be treated with a degree of caution. However,
information from large numbers of patients confirm that most
patients will experience at least one adverse event, and that
substantial minorities will experience common opioid adverse
events of dry mouth, nausea, and constipation, and will not
continue treatment because of intolerable adverse events.Arthritis Research & Therapy    Vol 7 No 5    Moore and McQuay 
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